Finding better doses of blood cancer drugs for multiple myeloma and Waldenstrom macroglobulinaemia
Compares different dosing strategies of cancer drugs in adults with multiple myeloma or Waldenstrom macroglobulinaemia.
Plain-language title generated from the registry record
Registry title: BLOOD-dose: A Platform Trial Evaluating Dose Optimization in Hematological Diseases.
Key facts
- Where
- Aalborg, Aarhus, Copenhagen, Odense, and Roskilde, DenmarkSee the 5 sites
- Phase
- Phase 4
Where in Denmark
- Aalborg University HospitalAalborg, DenmarkNo longer taking part
- Aarhus University HospitalAarhus, DenmarkNo longer taking part
- Copenhagen University Hospital, RigshospitaletCopenhagen, DenmarkNo longer taking part
- Odense University HospitalOdense, DenmarkNo longer taking part
- Roskilde University HospitalRoskilde, DenmarkNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Anne Louise Tølbøll Sørensen
- Trial code
- NCT07474961EU 2026-525658-13-00
- Record updated
- 16 March 2026
- Original description
BLOOD-dose is a multicentre, adaptive, randomized, multidomain platform trial designed to optimize treatment dosing strategies in adult patients with haematological diseases.Read full original descriptionShow less
A Multicentre, Adaptive, Randomised, Multidomain, Platform Trial for Dose Optimization in the Treatment of Adult Patients With Haematological Diseases (BLOOD-dose): Core Protocol
BLOOD-dose is a multicentre, adaptive, randomized, multidomain platform trial designed to optimize treatment dosing strategies in adult patients with haematological diseases.
The BLOOD-dose core protocol outlines the overall clinical trial design that applies to all included interventions, while domain-specific appendices (DSA) detail the unique characteristics of each domain and specify domain-specific interventions.
New domains will be incorporated over time to address distinct dose-optimization research questions across different haematological conditions and interventions.
Inclusion: Participants of any sex who are at least 18 years of age at the time of providing informed consent; Participant diagnosed with a haematological disease, i.e. any disorder that primarily affects the blood, bone marrow, the lymphatic system and/or blood-forming organs; Should be eligible for participation in at least one of the currently active domains; Capable of giving signed informed consent for each applicable DSA(s). By consenting to a domain, participants also consent to participation in BLOOD-dose.
Exclusion: Any condition that, in the opinion of the investigator, impairs the participant's ability to understand trial procedures, provide informed consent and/or interfere with participation and/or compliance in the trial; Domain eligibility criteria: each domain has its own specific eligibility criteria detailed in each DSA; The participant tient is expected to live less than 3 months, as judged by the investigator.